Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping
Open Access
- 2 May 2019
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 14 (7), e137-e139
- https://doi.org/10.1016/j.jtho.2019.04.021
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation (1908085MH260)
- Hefei Municipal Independent Innovation Policy (J2018Y01)
This publication has 5 references indexed in Scilit:
- Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung CancerClinical Cancer Research, 2019
- MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancerRevue des Maladies Respiratoires, 2018
- Cancer Statistics, 2018CA: A Cancer Journal for Clinicians, 2018
- Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung CancerClinical Cancer Research, 2017
- Cancer statistics, 2017CA: A Cancer Journal for Clinicians, 2017